National Cancer Institute's 'RAS Project' Takes Aim at Common Cancer-Driving Protein | Lung Cancer Dispatch |

The National Cancer Institute (NCI) is organizing a massive collaborative initiative between its laboratory and hundreds of outside researchers to discover cancer treatments targeting a class of genes called RAS genes and their products, RAS proteins. RAS genes, including their most common form, KRAS, are mutated in one-third of all cancers. Although the important role of RAS in cancer has been known for over 30 years, no treatments targeting RAS have been developed so far, because RAS proteins lack a 'binding site' where drugs could attack. However, recent research has uncovered potential weaknesses in RAS that future treatment might exploit. The NCI's RAS Project aims to 'crowdsource' the expertise of many researchers to better understand and tackle RAS.